Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer
- 31 October 2006
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 103 (1) , 195-198
- https://doi.org/10.1016/j.ygyno.2006.02.024
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Optimizing primary chemotherapy in ovarian cancerHematology/Oncology Clinics of North America, 2003
- Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancerPublished by Wolters Kluwer Health ,2002
- Systematic Review of First-Line Chemotherapy for Newly Diagnosed Postoperative Patients with Stage II, III, or IV Epithelial Ovarian CancerGynecologic Oncology, 2002
- CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancerBritish Journal of Cancer, 1999
- Prognostic value of serial CA125 measurements during chemotherapy for patients with advanced ovarian cancerInternational Journal of Gynecologic Cancer, 1997
- For stage III epithelial ovarian cancer the initial level of expression of CA125 does not correlate with survival in women who respond to treatmentInternational Journal of Gynecologic Cancer, 1996
- A risk model for ovarian carcinoma patients using CA 125: Time to normalization renders second-look laparotomy redundantCancer, 1996
- Tumor markers in the management of patients with ovarian cancerCancer Treatment Reviews, 1995
- Prognostic value of CA 125 in advanced ovarian cancerGynecologic Oncology, 1992
- Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group.Journal of Clinical Oncology, 1989